A graft vs. myeloma (GVM) effect has been suggested in transplant studies and has been demonstrated as a ''proof of principle'' concept using DLI to treat relapsed myeloma [24] . However outcomes after DLI for relapsed myeloma have been disappointing [25] calling in to question the potential efficacy of nonmyeloablative allogeneic stem cell transplantation. Large series of allogeneic SCT are not available to guide treatment decisions.